About Sirtex
Sirtex is a company based in Sydney (Australia) founded in 1991 was acquired by CDH in June 2018. It operates as a Direct-to-Consumer (D2C) and Professional Services. Sirtex has completed 1 acquisition, including OncoSec Medical. Sirtex offers products and services including SIR-Spheres Y-90 Resin Microspheres, LAVA Liquid Embolic System, and SIROS INSYTE with SurePlan LiverY90. Sirtex operates in a competitive market with competitors including RefleXion, Alpha Tau Medical, Mevion Medical Systems, ZAP-X and ABK Biomedical, among others.
- Headquarter Sydney, Australia
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sirtex Medical Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
CDH
(Jun 14, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sirtex
Sirtex offers a comprehensive portfolio of products and services, including SIR-Spheres Y-90 Resin Microspheres, LAVA Liquid Embolic System, and SIROS INSYTE with SurePlan LiverY90.
Used for treating unresectable liver tumors and metastases.
Designed for embolization in various medical treatment procedures.
Supports planning and delivery of liver cancer treatments.
People of Sirtex
Unlock access to complete
Sales and Marketing
39 people
Leadership Team
12 people
Software Development Team
6 people
Senior Team
6 people
Human Resources and Administration
3 people
Finance and Accounting
2 people
Operations Team
2 people
Market Team
2 people
Unlock access to complete
Funding Insights of Sirtex
Detailed funding history for Sirtex
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Sirtex
Sirtex has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include China Grand Pharmaceutical and Healthcare and CDH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and private debt firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Finished formulations and APIs are manufactured for therapeutic categories.
|
Locked | Locked | Locked |
Investor details for Sirtex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sirtex
Sirtex has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include OncoSec Medical.
Investment portfolio details for Sirtex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Intratumoral immunotherapies are developed to harness immune responses against cancer.
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Sirtex
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Sirtex
Detailed financials for Sirtex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sirtex Comparisons
Peer comparison for Sirtex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sirtex
Sirtex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RefleXion, Alpha Tau Medical, Mevion Medical Systems, ZAP-X and ABK Biomedical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biology-guided radiotherapy systems are provided for cancer treatment.
|
|
| Locked | Locked | Locked |
Radiotherapy technique for solid tumors is developed using alpha-emitting seeds.
|
|
| Locked | Locked | Locked |
Proton therapy systems are supplied for cancer radiation treatment.
|
|
| Locked | Locked | Locked |
Developer of gyroscopic radiosurgery platform
|
|
| Locked | Locked | Locked |
Imageable embolic devices are developed for hypervascular tumors.
|
|
| Locked | Locked | Locked |
Targeted radiopharmaceuticals are developed for solid tumor treatment.
|
Detailed competitors of Sirtex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sirtex
Complete news archive for Sirtex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sirtex
Sirtex was founded in 1991.
Sirtex is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Sirtex is focused on the development and distribution of innovative medical devices for the treatment of liver cancer and related conditions. The company specializes in products like SIR-Spheres Y-90 Resin Microspheres for treating unresectable liver tumors and metastases, alongside other solutions such as the LAVA Liquid Embolic System for embolization procedures. Operating in the healthcare sector, Sirtex serves professionals and patients globally through offices in the United States, Australia, Germany, and Singapore. Their offerings are tailored to address critical needs in oncology, providing targeted therapies and support for complex medical challenges.
Sirtex's top competitors include RefleXion, Alpha Tau Medical and Starget Pharma.
Sirtex offers SIR-Spheres Y-90 Resin Microspheres, LAVA Liquid Embolic System, and SIROS INSYTE with SurePlan LiverY90.
Sirtex has made 1 acquisition, including OncoSec Medical.
Sirtex has 2 investors. Key investors include China Grand Pharmaceutical and Healthcare, and CDH.